Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 801–900 of 2,656
Hong, S., Han, K., Kim, K., & Park, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02846-x · Cited by 12
“Three recent large-scale clinical trials of SGLT2 inhibitors that focused on people with CKD and assessed primary kidney outcomes demonstrated clear [15–17].”
InfluentialAnumas, S., & Inagi, R. (2025) · Nephrology · doi:10.1111/nep.70098 · Cited by 12
Shu, H.-P., Wang, Y., Li, X., Zhang, L., Wei, Z., Song, Y., Chen, J., Cheng, H. W., Chen, C., Liang, W., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01829-2 · Cited by 10
Azegami, T., Kaneko, H., Okada, A., Suzuki, Y., Aoyama, K., Nakayama, T., Fujiu, K., Takeda, N., Morita, H., Yokoo, T., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70020 · Cited by 10
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
Mazzieri, A., & Marcon, L. M. R. (2025) · Biomedicines · doi:10.3390/biomedicines13092123 · Cited by 13
“More recently, “The Study of Heart and Kidney Protection With Empagliflozin” (EMPA-KIDNEY) [100] was designed to evaluate the effect of empagliflozin on the progression of renal and cardiovascular disease in a wide variety of patients with chronic kidney disease, with and without diabetes (54% of…”
Salah, H. M., Ambrosy, A. P., Biegus, J., Bocchi, E. A., Butler, J., Chioncel, O. D., Cotter, G., Davison, B. A., Dzudié, A., Freund, Y., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.09.020 · Cited by 11
2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus
Zhao, J., Zhang, S., Wang, Q., Tian, X., Chen, Y., Li, M., & Zeng, X. (2025) · Rheumatology and Immunology Research · doi:10.1515/rir-2025-0017 · Cited by 10
Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease
Bartholdy, K. V., Johansen, N. D., Skaarup, K. G., Modin, D., Landler, N. E., Langhoff, A. C. F., Ottosen, C. I., Espersen, C., Dons, M., Borchsenius, J., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2500158 · Cited by 18
Lin, P., Zeng, B., Hsu, C., Suen, M., Hung, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · Biomolecules · doi:10.3390/biom15111622 · Cited by 8
Blum, M. F., Mehta, S., Surapaneni, A., Carrero, J. J., Zhang, D. “., Inker, L. A., Horwitz, L. I., Blecker, S., Shin, J., & Grams, M. E. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000902 · Cited by 9
Guidelines on primary healthcare for type 2 diabetes in China, 2025
Jia, W., Zhu, D., Guo, L., Chen, L., Cai, C., & Song, J. (2025) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003765 · Cited by 11
Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies
Speeckaert, R., Delrue, C., & Speeckaert, M. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030921 · Cited by 17
Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease
Al-Masri, S., Coelho, J. N., & Thomas, L. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1747053 · Cited by 14
Kim, D. J., Sheu, W. H., Chung, W., Yabe, D., Ha, K. H., Nangaku, M., Tan, E. C., Node, K., Yasui, A., Lei, W., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13959 · Cited by 9
Jhund, P. S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15171 · Cited by 8
Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective
de Pouvourville, G., Rossignol, P., Boussahoua, M., Chevalier, J., Gabb, P. D., Poulnais, R., Verboux, D., Rao, N., Sörstadius, E., & Sánchez, J. J. G. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02574-2 · Cited by 10
Murakoshi, M., Kobayashi, T., Kihara, M., Ueda, S., Suzuki, Y., & Gohda, T. (2023) · Nephrology · doi:10.1111/nep.14207 · Cited by 8
“Recently, the EMPA-Kidney trial further expanded the evidence of the DAPA-CKD trial by including patients with CKD with macroalbuminuria and micro- and normoalbuminuria, indicating that SGLT2 inhibitors may be useful for a wide range of patients with CKD.3 Many studies have reported the renoprotective effects of SGLT2…”
BackgroundInfluentialNabrdalik-Leśniak, D., Nabrdalik, K., Irlik, K., Janota, O., Kwiendacz, H., Szromek‐Białek, P., Maziarz, M., Stompór, T. P., Gumprecht, J., & Lip, G. Y. H. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2023.0039 · Cited by 13
A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes
Cowart, K., Coon, S. A., & Carris, N. W. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231190443 · Cited by 11
“7,35 Without primary evidence from a CV outcomes trial to confirm bexagliflozin’s impact on CV risk, it is unknown how it will differentiate itself among the other four SGLT2 inhibitors.”
BackgroundPlasma Biomarkers and Incident CKD Among Individuals Without Diabetes
Le, D., Chen, J., Shlipak, M. G., Ix, J. H., Sarnak, M. J., Gutiérrez, O. M., Schelling, J. R., Bonventre, J. V., Sabbisetti, V. S., Schrauben, S. J., et al. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100719 · Cited by 10
Kidneys in heart failure: Impact of flozins
Stompór, T. P., & Winiarska, A. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97844 · Cited by 9
“It is worth emphasizing that 34.2% of patients randomized to empagliflozin and 34.8% of those receiving placebo had eGFR 30 ml/min/1.73 m 2 [52].”
BackgroundInfluentialModeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
Clemmer, J. S., Yen, T. E., & Obi, Y. (2023) · Physiological Reports · doi:10.14814/phy2.15836 · Cited by 10
“…and rate of albuminuria were largely determined by glomerular capillary pressure (Figure 1) and by increasing baseline glomerular permeability to albumin to reach levels similar to the lower range (non-diabetic end) of the EMPA-KIDNEY and DAPA-CKD trials (Heerspink et al., 2020; The et al., 2023).”
BackgroundInfluentialHadjadj, S., Cooper, M. E., Steubl, D., Petrini, M., Hantel, S., Mattheus, M., Wanner, C., & Thomas, M. C. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100783 · Cited by 10
Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes
Popovic, D. S., Patoulias, D., Gnudi, L., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155763 · Cited by 9
Schork, A., Eberbach, M.-L., Bohnert, B. N., Wörn, M., Heister, D. J., Eisinger, F., Vogel, E., Heyne, N., Birkenfeld, A. L., & Artunç, F. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000535643 · Cited by 8
Brockmeyer, M., Parco, C., Vargas, K. G., Westenfeld, R., Jung, C., Kelm, M., Roden, M., Akbulut, C., Schlesinger, S., Wolff, G., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-023-01858-8 · Cited by 9
Lyu, Y. S., Hong, S., Lee, S. E., Cho, B. Y., & Park, C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02155-9 · Cited by 10
“The recent research of SGLT-2 inhibitors revealing the lower incidence of chronic kidney disease (CKD) progression have established them as essential medications for individuals with diabetic nephropathy [11, 12].”
BackgroundArgaiz, E. R., Morales‐Juárez, L., Razo, C., Ong, L., Rafferty, Q., Rincón-Pedrero, R., & Gamba, G. (2024) · Gaceta Médica de México · doi:10.24875/gmm.m24000830 · Cited by 19
Spasovski, G. B., Rroji, M., Hristov, G., Bushljetikj, O., Spahia, N., & Bushletikj, I. R. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0227 · Cited by 13
Investigational new drugs for the treatment of chronic renal failure: an overview of the literature
Terzo, C., Gembillo, G., Cernaro, V., Longhitano, E., Calabrese, V., Casuscelli, C., Peritore, L., & Santoro, D. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326624 · Cited by 9
“(P 0,001) [24].”
Egbuna, O. I., Audard, V., Manos, G., Tian, S., Hagos, F. T., & Chertow, G. M. (2024) · Glomerular Diseases · doi:10.1159/000538255 · Cited by 11
Improving Kidney Disease Care: One Giant Leap for Nephrology
Provenzano, M., Hu, L., Tringali, E., Senatore, M., Talarico, R., Dio, M. D., Ruotolo, C., Manna, G. L., Garofalo, C., & Zaza, G. (2024) · Biomedicines · doi:10.3390/biomedicines12040828 · Cited by 8
Nangaku, M., Herrington, W. G., Goto, S., Maruyama, S., Kashihara, N., Ueki, K., Wada, J., Watada, H., Nakashima, E., Lee, R., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02489-4 · Cited by 10
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · JMIR Research Protocols · doi:10.2196/56067 · Cited by 9
“The effects are similar in patients with nondiabetic CKD, reducing the risk of CKD progression and death by renal or cardiovascular causes by 30% to 40% [11,12].”
BackgroundSingh, A. K., Misra, A., Das, A. K., Behl, A., Srivastava, A., Paneerselvam, A., Chidambaram, B., Saboo, B., Sethi, B. K., Makkar, B. M., et al. (2023) · Journal of the Association of Physicians of India · doi:10.59556/japi.71.0422 · Cited by 12
The early diagnosis and treatment of chronic renal insufficiency
Hahn, K. M., & Strutz, F. M. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0072 · Cited by 20
An Update on Viral Infection-Associated Collapsing Glomerulopathy
Fisher, M. C., Ross, M. J., DiFranza, L. T., & Reidy, K. J. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.12.007 · Cited by 8
Alyaydin, E., Parianos, D., Hermes‐Laufer, J., Nägele, M. P., Castro, L., Παπαθανασίου, Μ., Reinecke, H., & Flammer, A. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10465-z · Cited by 8
Hummelgaard, S., Hvid, H., Birn, H., Glerup, S., Tom, N., Bilgin, M., Kirchhoff, J. E., & Weyer, K. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00065.2024 · Cited by 11
Olsen, E., Jamerson, K., Schmieder, R. E., Søraas, C. L., Mariampillai, J. E., Mancia, G., Kjeldsen, S. E., Heimark, S., Mehlum, M. H., Liestøl, K., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.12.021 · Cited by 14
Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
Tang, M., Morieri, M. L., Kalim, S., & Doria, A. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000620 · Cited by 8
Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer
Terashita, M., Yazawa, M., Murakami, N., Nishiyama, A., Electrolyte Winter Seminar Collaborative Group, Fujimaru, T., Fujita, Y., Hirose, K., Kawada, K., Monkawa, T., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02635-6 · Cited by 8
“Clinical studies have demonstrated that SGLT2 inhibitors improve cardiac [3, 4] and renal outcomes [5] in diabetic and non-diabetic conditions, including CKD [6, 7] and heart failure [8].”
Sánchez-Ospina, D., Mas, S., Palencia, M. M., Hijazi-Prieto, B., Sánchez, C. G., Carcedo, S. P., Albo, M. R., Egido, J., Ortíz, A., González‐Parra, E., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf123 · Cited by 19
Aldosterone synthase inhibition in chronic kidney disease
Theodorakopoulou, M. P., Iatridi, F., & Sarafidis, P. A. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001089 · Cited by 10
Prevalence of reduced eGFR in European adults using KDIGO and age-adapted eGFR thresholds
Astley, M. E., Chesnaye, N. C., Gambaro, G., Ortíz, A., Hallan, S. I., Carrero, J. J., Ebert, N., Eriksen, B. O., Faucon, A., Ferraro, P. M., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf112 · Cited by 11
An update on corticosteroid treatment for IgA nephropathy
Ghaddar, M., Barratt, J., & Barbour, S. J. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000881 · Cited by 10
Nutritional Treatment as a Synergic Intervention to Pharmacological Therapy in CKD Patients
Giannese, D., D’Alessandro, C., Panichi, V., Pellegrino, N., & Cupisti, A. (2023) · Nutrients · doi:10.3390/nu15122715 · Cited by 11
“The nephroprotection and antiproteinuric effects, independently from achieving good glucose control, are now well known: in randomized controlled trials, the use of SLGT2 inhibitors reduces progression to kidney disease, reduces hospitalizations and cardiovascular death, particularly in the case of overt proteinuria […”
BackgroundCardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
Charytan, D. M., Mahaffey, K. W., Jardine, M., Cannon, C. P., Neal, B. C., Heerspink, H. J. L., Agarwal, R., Bakris, G. L., de Zeeuw, D., Levin, A., et al. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003270 · Cited by 12
Latest pharmaceutical approaches across the spectrum of heart failure
Bismpos, D., Wintrich, J., Hoevelmann, J., & Böhm, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10389-8 · Cited by 11
Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure
Cleland, J. G. F. (2024) · Circulation · doi:10.1161/circulationaha.123.068089 · Cited by 10
“…the effect is modest ( 10 fewer cases of end-stage renal disease per 1,000 patient-years of treatment), many of these patients were hypertensive and few were taking loop diuretics and therefore it is not clear that it is appropriate to extrapolate these findings to patients with heart failure (15).”
BackgroundMedical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease
Kim, J. A., Kim, S. E., Hachem, K. E., Virk, H. U. H., Alam, M., Virani, S. S., Sharma, S. K., House, A. A., & Krittanawong, C. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.06.013 · Cited by 7
The interaction between non-coding RNAs and SGLT2: A review
Jarosz-Popek, J., Eyileten, C., Gager, G. M., Nowak, A., Szwed, P., Wicik, Z., Palatini, J., von Lewinski, D., Sourij, H., Siller-Matula, J. M., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131419 · Cited by 9
Sodium-glucose cotransporter 2 inhibitors and cardiorenal outcomes in kidney transplantation
Mahalwar, G., Mathew, R. O., & Rangaswami, J. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000948 · Cited by 10
New guidelines and therapeutic updates for the management of lupus nephritis
Desai, S. B., Ahdoot, R. S., Malik, F., Obert, M., & Hanna, R. M. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000969 · Cited by 10
Safety Profile and Effectiveness of Dapagliflozin in Pediatric Patients with Chronic Kidney Disease
Reeth, O. V., Caliment, A., Garcia, I. D. L. F., et al. (2024) · American Journal of Nephrology · doi:10.1159/000539300 · Cited by 7
Takeuchi, S., Kohno, T., Goda, A., Shiraishi, Y., Kitamura, M., Nagatomo, Y., Takei, M., Nomoto, M., Soejima, K., Kohsaka, S., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132190 · Cited by 7
ASHCHERKIN, N., Abdalla, A., Gupta, S., Bhatt, S. K., Yee, C., & Cartin‐Ceba, R. (2024) · Acute and Critical Care · doi:10.4266/acc.2023.01046 · Cited by 8
Ambery, P., Greasley, P. J., Menzies, R. I., Brynne, L., Kulkarni, S., Oscarsson, J., & Davenport, A. P. (2024) · Clinical Science · doi:10.1042/cs20240605 · Cited by 8
Updates in Chronic Kidney Disease
Johnson, H. N., & Prasad‐Reddy, L. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241262381 · Cited by 10
Chen, A. X., Fletcher, R., Neuen, B. L., Neal, B. C., & Arnott, C. G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15751 · Cited by 12
“Further, following the publication of the CREDENCE trial, the EMPA-KIDNEY trial (published in 2023) of empagliflozin 8 and the DAPA-CKD trial (published in 2020) of dapagli-flozin 9 confirmed the reno-protective benefits of SGLT2 inhibitors in CKD regardless of underlying diabetes status.”
InfluentialLin, D. S., Lee, J., Huang, K., Lin, T., & Lo, H.-Y. (2024) · Diabetologia · doi:10.1007/s00125-024-06257-7 · Cited by 11
Chronic kidney disease in older adults: challenges and opportunities for the primary care provider
Brady, B. M., Suffoletto, J.-A., Sankary, R., & Chertow, G. M. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02638-4 · Cited by 10
Osawa, K., Ohya, M., Yamamoto, S., Nakashima, Y., Tanaka, Y., Yamano, Y., Takatsuka, T., & Araki, S. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02590-8 · Cited by 10
Konta, T., Asahi, K., Tamura, K., Tanaka, F., Fukui, A., Nakamura, Y., Hirose, J., Ohara, K., Shijoh, Y., Carter, M., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02600-9 · Cited by 7
Emanuelsson, F., Jensen, J., Omar, M., Jürgens, M., Kistorp, C., Brandt, N., Møller, J. E., Schou, M., Bechmann, L. E., Larsen, E. L., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.015 · Cited by 8
Inside CKD: Cost-Effectiveness of Multinational Screening for CKD
Tangri, N., Oh, K., Choo, J. C. J., Jadoul, M. Y., Ärnlöv, J., Batista, M. C., Christiansen, C. F., Chernin, G., Retat, L., Card-Gowers, J., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.01.020 · Cited by 9
Jimba, T., Kaneko, H., Suzuki, Y., Okada, A., Azegami, T., Ko, T., Fujiu, K., Morita, H., Takeda, N., Hayashi, K., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae094 · Cited by 9
Sever, P., Rostamian, S., Whiteley, W. N., Ariti, C. A., Godec, T. R., Gupta, A. K., Mackay, J. A., Whitehouse, A., & Poulter, N. R. (2025) · Heart · doi:10.1136/heartjnl-2024-325104 · Cited by 14
Wu, D., Hsu, B., & Lin, Y. (2025) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_275_24 · Cited by 14
Mazzotta, R., Garofalo, M., Salvi, S., Orlandi, M., Marcaccini, G., Susini, P., Checchi, L., Palazzuoli, A., Mario, C. D., Pieroni, M., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15293 · Cited by 12
Lan, N. S. R., Hiew, J., Ferreira, I., Ritter, J. C., Manning, L. A., Fegan, P. G., Hamilton, E. J., & Dwivedi, G. (2025) · Physiological Reports · doi:10.14814/phy2.70415 · Cited by 7
“…to improve renal and cardio-vascular outcomes in patients with type 2 diabetes and al-buminuric CKD. (Bakris et al., 2020; Heerspink et al., 2020; Herrington et al., 2023; Perkovic et al., 2019, 2024; Pitt et al., 2021) Importantly, these therapies have mechanisms of action that target…”
Mechanisms and therapeutic potential of multiple forms of programmed cell death in renal fibrosis
Chen, Y., Liu, F., Dai, R., Cheng, M., Wang, W., Sang, Y., Wei, L., Wang, Y., & Zhang, L. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111926 · Cited by 11
Cowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01761-4 · Cited by 13
An, Y., & Zhang, H. (2025) · American Journal of Nephrology · doi:10.1159/000546079 · Cited by 10
Diallo, A., Villard, O., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16561 · Cited by 9
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Zhao, S., Liu, H., & Liu, A. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04910-6 · Cited by 12
“Beyond glycemic control, SGLT2i have demonstrated robust benefits in reducing cardiovascular events, slowing chronic kidney disease progression, and decreasing mortality in broad patient populations, regardless of diabetes status [25–27].”
Zhou, J., Williams, C., Staplin, N., Judge, P. K., Mayne, K. J., Agrawal, N., Arimoto, R., Green, J. B., Cherney, D. Z. I., Tuttle, K. R., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103338 · Cited by 13
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis
Ceasovschih, A., Balta, A., Aldeen, E. S., Bianconi, V., Barkas, F., Şener, Y. Z., Jakubová, M., Yılmaz, M. B., Banach, M., Șorodoc, L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101061 · Cited by 12
Repurposing metabolic drugs as anti-inflammatory agents
Hogan, A. E., Davis, C., Jenkins, B. J., Jones, N., & O'Shea, D. B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.003 · Cited by 15
Wu, Y., Cao, Y., Feng, L., Yan, Y., Ye, H., Tang, K., Wei, Y., Chen, T., Guo, X., & Ma, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157182 · Cited by 11
Zou, Y., Li, J., Xu, C., & Yan, B. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117277 · Cited by 13
Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review
Zhang, H., Chen, J., Wang, N., Chen, W., Xu, Y., & Gui, D. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70077 · Cited by 9
Taylor, R. S., Heerspink, H. J. L., Buyse, M. E., Ciani, O., Detournay, B., Gallego, D., Mauro, J. C. J., Sinha, S., Trapero‐Bertran, M., & Inker, L. A. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103465 · Cited by 10
“36 The pink dashed lines are the 95% pointwise Bayesian prediction bands computed from the model.”
InfluentialCosentino, N., Trombara, F., Metrio, M. D., Molinari, C., Genovese, S., Pontone, G., & Marenzi, G. (2025) · Pharmaceuticals · doi:10.3390/ph18081202 · Cited by 8
Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review
Tuttle, K. R., Ji, L., Mathieu, C., & Rosen, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70180 · Cited by 8
“63 Overall, empagliflozin reduced the composite of kidney outcomes or cardiovascular death compared with placebo by 28% and slowed the rate of eGFR decline in participants with and without diabetes.”
Huang, S. Y., Tamaroff, J. G., Farber‐Eger, E. H., Chow, N., Siddiqi, H. K., Brinkley, D. M., Menachem, J. N., Rali, A. S., Lindenfeld, J. M., Ooi, H., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102710 · Cited by 17
Kim, H., Kim, B. S., Kim, H., Lee, J., Jo, H. H., Kim, D. W., Shin, J., & Sung, K. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.194 · Cited by 12
New kidneys, old risks: cardiovascular challenges after transplantation
Craenenbroeck, A. H. V., Chinnappa, S., Dounousi, E. C., Fernández‐Fernández, B., Iatridi, F., Mark, P. B., Piko, N., Stegbauer, J., Torino, C., Vogt, L., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf239 · Cited by 13
Kidney diseases and the thyroid: interactions and consequences
Brenta, G. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01203-y · Cited by 10
Li, T., Chen, K., Sun, Y., & Zhang, L. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1760654 · Cited by 13
Vecchio, L. D., Cases, A., Eisenga, M. F., Małyszko, J., Barratt, J., & Bolignano, D. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag014 · Cited by 12
Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research
Granata, S., Barberio, L., D’Agostino, R., Sorace, F., Leone, F., Pellegrino, D., Stallone, G., Provenzano, M., & Zaza, G. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07796-w · Cited by 8
“…r i s k o f p r o g r e ss i o n o f k i d n e y d i s e a s e o r d e a t h f r o m c a r d i o v a s c u l a r c a u s e s t h a n p l a c e b o [ 157 ] P r e c l i n i c a l ( i n v i v o ) S t r e p t o z o t o c i n - i n d u c e d d i a b e t i c r a t s ; D i a b e t i c k i d n e y d i s e…”
Zeng, G., Bidel, Z., Yang, Q., Canoy, D., Woodward, M., Lewis, J., Kjeldsen, S. E., Cushman, W. C., Yuan, J., Teo, K. K., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00367-3 · Cited by 13
Kueh, M. T. W., Yeo, J. Q., Chen, Y., Chua, N. Y. Z., Koh, H. L., Khaw, S. P., Jabbar, H., Wang, J., Lee, K. S. S., Chin, Y. H., et al. (2026) · Liver International · doi:10.1111/liv.70747 · Cited by 16
Kittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 25
Alanazi, W. A., Alharbi, T., El-Nagar, D. M., Albogami, A. M., & Alswayyed, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061683 · Cited by 9
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151427 · Cited by 10
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.